{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-033157","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.772607+00:00","generated_at":"2026-06-04T23:17:14.078545+00:00","sec_items":["2.02","8.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TriSalus reports preliminary Q4 revenue $5.7M (+77% YoY) and FY23 revenue $18.5M (+49% YoY)","bullets":["Preliminary Q4 2023 revenue $5.7M (up 77% vs Q4 2022); full-year 2023 revenue $18.5M (up 49% vs 2022).","Gross margin improved to ~90% in Q4 2023 and ~86% for FY2023, vs 75% and 82% a year ago.","Cash and equivalents $11.8M as of Dec 31, 2023; expects liquidity to fund operations into Q2 2024.","Revenue entirely from TriNav Infusion System; final audited financials not yet released.","Preliminary estimates are unaudited and subject to change; auditor has not performed any procedures."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-033157","json":"https://secwatch.observer/filing/0001104659-24-033157.json","markdown":"https://secwatch.observer/filing/0001104659-24-033157.md","text":"https://secwatch.observer/filing/0001104659-24-033157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924033157/0001104659-24-033157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924033157/tm248546d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:17:14.078545+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"708537db5498f140fe7bb70df1df165955e1d76a","claim":"TriSalus Life Sciences, Inc. reported fiscal year-ended December 31, 2023 results: revenue approximately $5.7 million for the fourth quarter of 2023.","evidence_excerpt":"On March 11, 2024, TriSalus Life Sciences, Inc. (the “Company”) announced a preliminary unaudited financial update with respect to the Company’s fiscal year-ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924033157/0001104659-24-033157-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year-ended December 31, 2023"},{"label":"Revenue","value":"approximately $5.7 million for the fourth quarter of 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}